Deborah Weitzman, the Chief Executive Officer of Cardinal Health's Pharmaceutical and Specialty Solutions (PSS) segment, recently executed a stock sale involving 7,354 shares of the company. This transaction, detailed in a recent SEC filing, amounted to approximately $1.7 million. What makes this particular sale noteworthy is that despite divesting a significant number of shares, Weitzman's overall equity in Cardinal Health substantially increased by 47% during August. Her direct holdings now stand at 77,901 shares, valued at roughly $18.31 million. This event provides a fascinating look into executive stock management and compensation structures within major healthcare corporations.
The shares were sold at a weighted average price of $235.45, with individual transaction prices fluctuating between $235.17 and $237.63. Following this transaction, Weitzman's direct stake saw a 9% reduction from her previous holdings. However, this was more than offset by the acquisition of performance units, illustrating a common practice where executives receive stock-based compensation that can dramatically alter their ownership profile. Cardinal Health itself is a global powerhouse in healthcare products and services, boasting a market capitalization of $55.0 billion and trailing twelve-month revenues of $254.2 billion.
Cardinal Health's operational strength stems from its two primary divisions: Pharmaceutical and Medical. These segments are crucial in providing extensive distribution, logistics, and value-added services to a wide array of healthcare entities including hospitals, pharmacies, and clinics across multiple international markets. The company's competitive edge is fortified by its integrated distribution network, significant scale across its various operations, and enduring relationships with diverse healthcare providers. Employing nearly 59,000 individuals worldwide, Cardinal Health is a fundamental component of the global healthcare supply chain.
For investors, this transaction offers several insights. Weitzman's ability to sell shares while simultaneously increasing her stake underscores the intricacies of executive compensation plans, often involving performance-based awards. More importantly, her leadership of the Pharmaceutical and Specialty Solutions segment is a critical factor, as this division has been a primary driver of Cardinal Health's recent financial success. In the most recent fiscal quarter, this segment contributed $58.8 billion in revenue, marking a 6% increase, with segment profit surging by 21% to $645 million. The Specialty sector alone experienced over 25% growth throughout fiscal 2026. Company leadership remains optimistic about the Biopharma Solutions business, projecting continued robust growth in the coming fiscal year.
This insider transaction by Deborah Weitzman, while involving a notable sale of shares, ultimately reflects a significant expansion of her ownership in Cardinal Health. This outcome is largely attributable to performance-based awards that were granted earlier in August. The context of this executive's increased stake is particularly relevant given the strong financial performance of the Pharmaceutical and Specialty Solutions segment, which she oversees. This segment has been a key contributor to Cardinal Health's overall revenue and profit growth, reinforcing the company's position as a vital player in the global healthcare landscape.
